From the Editor's Desk...

The evidence supporting the use of proton beam radiotherapy in patients with hepatocellular carcinoma (HCC) is weak. Kim  et al. recruited 144 patients into a non-inferiority phase III randomised trial testing the hypothesis that proton beam radiotherapy (PBT) is non-inferior to radiofrequency ablation (RFA) in the treatment of patients with recurrent or residual HCC. Crossover was allowed if the assigned treatment was not technically feasible and occurred in 6 patients in the PBT arm and 19 in the RFA arm.

Source: Journal of Hepatology - February 15, 2021 Category: Gastroenterology Authors: Patrizia Burra, Frank Tacke, Vlad Ratziu, Stefan Zeuzem, Bruno Sangro, Paolo Angeli Tags: From the Editor's Desk Source Type: research